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Abstract 
Malignant tumor cells overexpress and release lipid vesicles called exosomes into the 
body fluids to facilitate their movement and metastasis to other parts of the body. It was found 
that an increased secretion of exosomes in the peripheral blood is correlated with lung cancer and 
melanoma metastasis. The hallmarks of exosomes are their highly curved surface (d = ~30-100 
nm) that is distinct from other extracellular lipid vesicles and their enrichment with the anionic 
lipid phosphatidylserine (PS) in the outer leaflet of the membrane bilayer. These properties 
provide an opportunity in selectively targeting exosomes as potential cancer biomarkers. We 
have developed a novel, minimally invasive, peptide-based diagnostic tool to detect synthetic 
liposomes that could be used to detect exosome oversecretion in cancer patients. The successful 
development of this diagnostic tool for cancer metastasis will help in the proper diagnosis and 
therapy for cancer patients. 
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Introduction 
Exosomes are a class of lipid membrane vesicles that are secreted by most cell types. 
They were previously believed to carry cell debris as part of normal cellular processes. Recent 
research has shown, however, that exosomes are secreted from live cells and carry proteins and 
RNAs, suggesting an important role in intercellular communication.1 The exact contents of an 
exosome depend on the cell of origin2. Although the specific mechanism of information transfer 
via exosomes between the host cell that secreted the exosomes and the target cell is not yet 
understood, the overall result of exosome-mediated intercellular transfer is the incorporation of 
host cell RNA into the target cell resulting in functional protein production and therefore a 
change in the physiological state.2  
 Exosomes are involved in stimulation and inhibition of the immune system3, and a highly 
sought after clinical application addresses metastatic cancer. Although exosomes are naturally 
shed by normal cells, abnormal and increased secretion of these particles occurs in a diseased 
state.  During cancer metastasis, malignant tumor cells spread from their original location to 
another site and are the cause of 90% of cancer-related 
deaths.4 Exosomes released by tumor cells are known to 
facilitate cancer metastasis (see Figure 1) and have been 
shown to express immune inhibitory effects, such as 
inducing T-cell apoptosis (cell death of white blood cells 
involved in immunity), blocking T-cell signaling as well as 
releasing pro-angiogenesis factors.5,6 Angiogenesis is a 
process that provides tumors with the necessary factors for growth and survival, such as blood, 
oxygen, nutrients, and waste removal. These features that are facilitated by exosomes may 
Figure 1. Secretion and function of exosomes 
in melanoma metastasis. 
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provide an interesting account of the in-depth workings of cancer and lead to diagnostic and 
therapeutic approaches. 
 It has been shown that exosomes are present in human blood plasma. Furthermore, it has 
been suggested that by using a minimally invasive blood test, exosomes secreted by tumor cells 
could be detected. Their detection can be associated with changes in tumor progression 
regardless of tumor type or location and could be useful in providing diagnostic information and 
aid to therapeutic decisions.2  The blood of metastatic cancer patients has been shown to have a 
significant increase in exosomes5 of about 300-400% when compared to normal volunteers.7,8 
Clinical methods currently being used to classify metastatic patients are not accurate or 
reproducible, are often problematic, and, further, do not indicate valuable information, such as 
whether or not treatment is reducing metastasis.9 A clinical tool currently used to investigate 
cancer metastasis is the process of biopsy, which involves drawing tissue samples from the body 
organ of interest, which is a very invasive technique.  
By using exosomes as biomarkers for metastatic cancer, it has been hypothesized that 
there will be a correlation between the amount of exosomes in the blood and tumor progression. 
This relationship, which would be determined periodically through analysis of minimally-
invasive blood draws, could allow for earlier detection of metastasis as well as the ability to 
determine the effectiveness and responses to treatments at an earlier date.5 One hallmark of shed 
exosomes is the enrichment of the anionic phospholipid phosphatidylserine (PS) in the outer 
leaflet of the membrane.1 Since exosomes are very small and difficult to detect using 
conventional optical methods, this project aims to develop a new approach on detecting 
exosomes based on peptide-lipid interactions and advance the detection and understanding of 
using exosomes as biomarkers of cancer metastasis. 
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 Bradykinin is a nine-residue 
cationic peptide (Figure 2) that was 
recently found by magnetic resonance 
studies to selectively bind to lipid 
vesicles that are enriched with 
negatively charged head groups. The 
amino acid sequence is RPPGFSPFR. This research group has also shown through NMR studies 
that the arginine residue serves as an anchor between the peptide and the membrane surface.10  
The Yin Lab has previously shown by fluorescence assay that an analogue of bradykinin attaches 
to synthetic lipid vesicles that contain anionic 
phospholipids and whose sizes fall within the 
range of exosomes.11  Further, the Yin lab has 
demonstrated that the binding properties of 
the monomeric peptide (Peptide 1) to isolated 
exosomes and exosomes in whole blood 
plasma are statistically identical in rats 
(Figure 3).  Finally, the Yin Lab synthesized 
an arginine-to-alanine (RtoA) mutant peptide 
(Peptide 5) as a negative control, which demonstrated no clear binding preference profile for 
either vesicle size or lipid composition. The small amount of binding that did occur could be due 
to the phenylalanine residues inserting into the membrane defects.21 
The diagnostic tools that were utilized are peptide-based molecules that bind with high 
affinity to lipid vesicles, which were used as synthetic models of exosomes.  It has been 
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demonstrated that putting a biologically active molecule into a dendrimeric scaffold and making 
the structure multivalent would render it to possess a higher affinity to its target.22 The Yin Lab 
has previously performed fluorescence enhancement assays the monomeric peptide (Peptide 1) 
and the trimeric peptide (Peptide 3), see Figure 4.10 Fluorescence enhancement relies on a 
fluorophore changing its partitioning coefficient by switching from a polar, aqueous environment 
to a nonpolar, phospholipid environment through binding, which leads to increased fluorescence 
intensity.18 Importantly, even though the relative fluorescence enhancement decreases from the 
synthetic lipid model to the exosomes, the decrease is small. Further, as the relative enhancement 
increases, the difference will likely decrease. The synthetic lipid models used can be seen in 
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Figure 5, and have been designed to closely mimic a biological membrane.19 As the diameter 
decreases, the curvature increases, as does the number of defects along the outer membrane.20   
Peptide 1 showed an increase in fluorescence intensity that is directly related to the 
decrease in liposome size at any lipid composition. Peptide 3 showed increase in fluorescence 
intensity corresponding to increase in 
the amount of phosphatidlyserine 
(PS), with the highest preference for 
30 nm LM3 and no size selection for 
LM1, indicating that multimerization 
of BK derivative resulted in an 
increased ability for curvature and PS 
sensing. However, Peptide 3 still showed a significant preference for 30 nm LM2 lipid vesicles, 
which contain 10% mol/mol of phospatidylserine.  
The new proposed scaffolds will allow for the creation of dimeric (Peptide 2) and 
tetramer dendrimeric (Peptide 4) peptides. Dendrimeric peptides, named from dendrites, the 
branching projection of neurons, are branching peptides. These scaffolds will then be decorated 
with the peptide of interest, which will be tagged with a fluorescent molecule that will allow 
visualization of the binding affinity of the peptide to tumor-secreted exosomes using biophysical 
assays. It is the hope that this project will lead to a peptide-based, novel diagnostic tool that will 
create an invaluable impact to cancer diagnosis and therapy. 
Procedure 
Peptide Synthesis. The peptide bradykinin (BK) was synthesized with microwave assisted solid 
phase peptide synthesis (SPPS) on Rink Amide AM resin (KGRPPGFSPFR) with an amide at 
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the C-terminus (see Figure 6). The ε-amine of the lysine residues was protected with the 
orthogonal protecting group methyl-trityl (Mtt) that could be selectively removed without 
affecting the other protecting groups of the resin-bound peptide. The free amine of the lysine was 
selectively revealed by Mtt deprotection using 1% trifluoroacetic acid in CH2Cl2. The free amine 
was then converted to the azide,12 and following confirmation of conversion using the Kaiser 
test, the N-terminal Fmoc protecting group was removed and then conjugated with the 
fluorescent reporter molecule 6-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)aminohexanoic acid 
(NBD-Ahx). The peptide was then cleaved from the resin, purified by reverse-phase HPLC, and 
characterized by mass spectrometry. 
 
 
Figure 6: Peptide synthesis route resulting in Peptide 1 
 
Scaffold Synthesis. The synthesis of tetrameric alkyne functionalized scaffold of type A (Figure 
7) could be completed with the formation of the amide bond between the benzoate alkyne (C) 
and the methyl-benzoate amine (B). The methylbenzoate amine fragment (B) was synthesized 
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from the reaction of t-butyl-(2-bromoethyl) carbamate and methyl 3,5-dihydroxybenzoate (F) 
following t-butyloxycarbonyl (BOC) deprotection of E. The benzoate alkyne (C) could be 
obtained from the hydrolysis of methylbenzoate alkyne of type D, which could be obtained by 
the conjugation of propargyl bromide with methyl 3,5-dihydroxybenzoate (F).  F could be 
accomplished with the esterification of 3,5-dihydroxybenzoate of type (G). The methylbenzoate 
alkyne of type D is the dimer scaffold.  
 
Figure 7: Retrosynthesis of the dendrimer scaffold. 
Dendrimer and Dimer Synthesis. The dendrimer and dimer were then synthesized from the 
appropriate scaffold, A and D respectively, and the functionalized peptide using copper-
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catalyzed azide-alkyne 1,3-dipolar cycloaddition (CuAAC), more commonly known as ‘Click’ 
chemistry15, see Figure 8. Following completion of the reaction, the peptide-small molecule 
conjugates were purified via reverse-phase HPLC and characterized by mass spectrometry.  
 
Figure 8: Structures of a) dendrimeric Peptide 4 and, b) dimeric Peptide 2.  
Liposome Preparation. Three lipid models (LM) were prepared: LM1, LM2, and LM3, each 
with 2 mM total lipid concentration utilizing the method described by Morton15. The models 
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contained varying amounts of palmitoyl-phosphatidylcholine (POPC), cholesterol, palmitoyl-
phosphatidylethanolamine (POPE), and palmitoyl-phosphatidylserine (POPS). LM1 contained 
70% POPC/15% POPE/15% cholesterol/0% POPS. LM2 contained 60% POPC/15% POPE/15% 
cholesterol/0% POPS, and LM3 contained 50% POPC/15% cholesterol/15% POPE/20% POPS. 
Following overnight incubation at 4°C in PBS buffer, pH 7.4, each model was extruded using the 
Liposofast LF-50 through a polycarbonate membrane with 400 nm, 100 nm, or 30 nm pore 
diameters to create three sizes for each LM.  
Fluorescence Enhancement. 1 μM solution of the dimer (peptide 2) and dendrimer (peptide 4) 
were prepared in PBS, pH 7.4. The concentration was adjusted to exactly 1 μM by taking an 
absorbance reading using the UV-Vis spectrophotometer. The plate was prepared as follows. The 
first row contained the blank samples, including PBS and the appropriate liposome model. The 
second and subsequent rows contained the appropriate liposome sample and the peptide. Using 
the fluorimeter and the corresponding software, the blank was subtracted from the sample to give 
fluorescence enhancement due only to the peptide binding to the liposome.  
Results and Discussion 
Fluorescence enhancement results for Peptide 2 and Peptide 4 are reported in Figure 9. 
Peptide 2 preferentially binds to 30 nm liposomes. There is no statistical difference between the 
binding affinities of Peptide 2 to LM2 and LM3 30 nm vesicles, and the binding affinity to LM1 
30 nm is greater than to LM2 and LM3 30 nm vesicles. The lack of preference for high levels of 
PS is evident, and is consistent with the selectivity trends observed in the monomeric peptide. 
Dendrimeric Peptide 4 does not bind to LM1, binds without size preference to LM2, and binds 
with increasing fluorescence intensity corresponding to an increase in the amount of PS.     
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Figure 9: Fluorescence enhancement due to Peptide 2 (left) and Peptide 4 (right).  
Compared to Peptide 1 and Peptide 3, Peptide 4 is more selective for PS concentration 
but less selective for curvature. But, the fluorescence intensity is four-fold decrease for LM3 30 
nm liposomes from Peptide 3 to Peptide 4.   
The significant decrease in fluorescence from Peptide 3 to Peptide 4 contradicts 
Liskamp’s observation that increasing the number of displayed peptides will increase the binding 
affinity22. This could be explained by recalling that bradykinin electrostatically interacts with the 
exosome by inserting the arginine residues, which are highly aromatic.  The scaffold of Peptide 4 
is not only cationic but is also highly aromatic because of the aromatic dendrimer scaffold, and 
could be inserting into the liposomal bilayer instead of the peptide. This would prevent 
fluorescence enhancement as a result of aromatic ring insertion in the bilayer and could 
significantly affect the fluorophore intensity.   
Peptide 2 was proposed to test this hypothesis, but the results can neither be used to 
confirm or reject the theory for Peptide 4. Primarily, there is still significant binding between the 
peptide and the liposomal membrane, resulting in fluorescence enhancement that is much larger 
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than the monomer. This shows that the peptide is in fact binding and not the scaffold, in this 
case. The scaffold is very small compared to the peptide and with less aromaticity. If the scaffold 
were binding, it could be due to increased aromaticity, which is seen in Peptide 4 but not Peptide 
2. This suggests that in order for the scaffold to not interfere with binding, the scaffold must 
contain less aromatic moieties than the peptide.   
Conclusions 
This paper reports on the synthesis and characterization of designed peptides that 
preferentially bind to highly curved lipid vesicles. Peptides 1, 2, 3, and 4 were designed from the 
peptide Bradykinin. We utilized solution phase 'Click' chemistry to prepare the trivalent peptide 
and the tetravalent dendrimeric peptide using the ε-azide on the Lys residue. Peptide 1 prefers 
highly curved liposomes that contain PS, and its curvature and PS sensing ability was further 
enhanced upon multimerization. Peptide 2 shows selectivity for vesicles with high curvature but 
no selectivity towards PS concentration. The trivalent Peptide 3 showed two-dimensional 
selectivity through its ability to discriminate variations in PS content as well as in its preference 
for lipid vesicles with the highest curvature. These observed properties were further enhanced in 
Peptide 4. Although the fluorescence enhancement due to the interaction of 30 nm LM 3 vesicles 
with Peptide 4 is weaker than the interaction with Peptide 3, improved selection for the highest 
curvature and PS content was achieved with Peptide 4.  
We have developed a series of peptide probes that preferentially bind to highly curved 
synthetic lipid vesicles and to rat exosomes. We expect that further design modifications will 
result in a peptide probe with the potential to be a diagnostic tool in the detection of exosomes 
released into the blood of patients with metastatic cancer. The investigation of the exosome 
binding properties of these peptides on human blood plasma samples is ongoing. This project 
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may lead to a novel method to evaluate cancer progression and, ultimately, be translated from 
bench to bedside in order to help save lives.  
Experimentals 
Chemistry General Methods 
All reactions were run under an inert atmosphere of N2 gas. Reaction solvents were anhydrous 
and of HPLC quality. All other reagents were purchased from Sigma Aldrich and used without 
further purification. Yields were calculated for material judged homogenous by thin layer 
chromatography and nuclear magnetic resonance (NMR). Thin layer chromatography (TLC) was 
performed on Merck Kieselgel 60 F254 plates, eluting with the solvent indicated, visualized by a 
254 nm UV lamp, and stained with an ethanolic solution of 12-molybdophosphoric acid. 
Glassware for reactions was oven dried at 125 °C prior to use.  Column flash chromatography 
was performed using Silica Gel Premium Rf, 60 Å, 200 x 400 mesh from Sorbent Technologies. 
Nuclear magnetic resonance spectra were acquired on a Bruker spectrometer; 300 MHz for 1H 
and 75 MHz for 13C. Chemical shifts for 1H NMR spectra are reported in parts per million (ppm) 
and referenced to the signal of residual nondeuterated chloroform at 7.26 ppm. Chemical shifts 
for 13C NMR and DEPT spectra are reported in parts per million (ppm) and referenced to the 
center line of the CDCl3 triplet at 77.23 ppm. Chemical shifts of the unprotonated carbons (‘C’) 
for DEPT spectra were obtained by comparison with the 13C NMR spectrum. Mass spectrometry 
was performed at the mass spectrometer facility of the University of Colorado Boulder, 
Department of Chemistry & Biochemistry on a ESI-qTOF-MS (electrospray-triple quadrupole-
time-of-flight mass spectrometer) from Applied Biosystems, PE SCIEX/ABI API QSTAR Pulsar 
Hybrid LC/MS/MS. Compounds with a ppm error less than 4% from HRMS were deemed pure. 
Compounds were named using ChemDraw. 
Coulup 16 
 
 
Preparation of Methyl 3,5dihydroxybenzoate (F)  
To a solution of 3,5dihydroxybenzoic acid (10 g, 0.064 mol) in MeOH (70 mL), sulfuric acid (2 
mL) was added.  The reaction mixture was refluxed (68 °C) for 25 hours and concentrated. The 
residue was dissolved in water and extracted with a 1:1 of CHCl3 : t-butyl-OH mixture, dried 
over Na2SO4, and concentrated.  The resulting residue was freeze dried overnight and then 
recrystallized from 100 mL of water at   70 °C.  Methyl 3,5dihydroxybenzoate was obtained as a 
colorless crystal (7.447 g, 68.3%).  Rf= 0.49 (30% EtOAc/DCM).  1H NMR (300 MHz, MeOD) 
δ 6.92 (d, J = 2.28 Hz, 2H), 6.47 (t, J = 2.29 Hz, 1H), 4.88 (s, 2H), 3.85 (s, 3H). 13C NMR (75 
MHz, MeOD) δ 52.52 (CH3), 108.23 (CH), 108.77 (CH), 133.03 (C), 159.80 (C), 168.67 (C). 
HRMS (ESI+) = calculated C8H8O4 (M+Na+) = 191.0315, found = 191.0317. 
 
 
Preparation of methyl 3-bis{2-[(tert-butoxycarbonyl)amino]ethoxy}benzoate17 (E) 
To a solution of methyl 3,5dihydroxybenzoate (0.065 g, 0.425 mmol) in dry DMF (0.52 M) was 
added K2CO3 (0.264 g, 1.91 mmol) and tert-butyl(3-bromopropyl)carbamate (0.25 g, 1.12 
mmol). The reaction mixture was stirred at 40°C for 16 hours. The mixture was then filtered and 
concentrated. The solution was taken up in ethyl acetate and washed with water (2x 10 mL) and 
MeO
O
OH
OH
MeO O
O O
NH
H
N
O
O
O
O
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brine (1x 10 mL), dried over Na2SO4, and concentrated. Compound 2 was obtained as a yellow 
powder (0.312 g, 83%). Rf= 0.77 (10% methanol in dichloromethane). 1H NMR (300 MHz, 
CDCl3) δ 7.17 (d, J = 2.34 Hz, 1H), 6.63 (t, J = 2.33 Hz, 1H), 4.03 (t, J = 5.10 Hz, 2H), 3.89 (s, 
2H), 3.53 (dd, J = 5.20, 10.46 Hz, 2H), 1.45 (s, 10H). 13C NMR (75 MHz, CDCl3) δ 28.53 
(CH3), 40.13 (CH2), 52.43 (CH3), 67.67 (CH2), 79.77 (C), 106.62 (CH), 108.23 (CH), 132.28 
(C), 155.98 (C), 159.73 (C), 166.71 (C). HRMS (ESI+) = calculated C22H34N2O8 (M+H+) = 
455.2390, found = 455.2388. 
O
O
O
O
NH2
NH2  
Preparation of methyl 3,5-bis(2-aminoethoxy)benzoate17 (B) 
Compound E  (0.062 g, 0.137 mmol) taken up in 1:1 v:v TFA/DCM solution (0.08 mL:0.08 mL) 
and stirred at room temperature for 30 minutes. The mixture was concentrated under reduced 
pressure, and lyophilized overnight. Compound B was obtained as a yellow oil (7 mg, 20%). Rf= 
0.47 (10% MeOH/DCM), visualized with Ninhydrin stain. 1H NMR (300 MHz, MeOD) δ 7.30 
(d, J = 2.08 Hz, 2H), 6.91 (t, J = 2.00 Hz, 1H), 4.31 – 4.25 (m, 5H), 3.90 (d, J = 1.49 Hz, 3H), 
3.39 (t, J = 4.77 Hz, 4H). 13C NMR (75 MHz, MeOD) δ 40.14 (CH2), 52.88 (CH3), 65.70 (CH2), 
107.64 (CH), 109.68 (CH), 133.62 (C), 160.61 (C), 167.80 (C).  
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Preparation of methyl 3,5-bis(prop-2-yn-1-yloxy)benzoate13 (D)  
Methyl 3,5-dihydroxybenzoate (4g, 23.79 mmol) was dissolved in dry DMF (0.52 M) and 
K2CO3 (8.22g, 59.5 mmol) was added. To this suspension, a solution of propargyl bromide in 
toluene (80 wt %, 5.13 mL) was added dropwise. Mixture was stirred at room temperature for 48 
hours and then taken up in 50 mL EtOAc, washed with excess water (3x100 mL), then washed 
with NaHCO3 (3x50mL), and brine (3x50mL). Organic layers combined, dried with Na2SO4, 
filtered, and concentrated under reduced pressure.  The product was recrystallized from a 1:1 
mixture of EtOAc/Hexanes (60 mL) by heating to 75°C and then lyophilized overnight.  
Compound D was obtained as a yellow powder (4.44 g, 77%). Rf= 0.54 (50% Hexanes/DCM). 
1H NMR (300 MHz, CDCl3) δ 7.30 (d, J = 2.38 Hz, 1H), 6.82 (t, J = 2.38 Hz, 1H), 4.74 – 4.70 
(m, 2H), 3.91 (s, 1H), 2.54 (t, J = 2.41 Hz, 1H). δ C (75 MHz, CDCl3) 52.52 (CH3), 56.28 (CH2), 
76.11 (CH), 77.36 (C), 78.10 (C), 107.68 (CH), 109.04 (CH), 132.31 (C), 158.66 (C). HRMS 
(ESI+) = calculated C14H12O4 (M+H+) = 245.0812, found = 245.0809 
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Preparation of 3,5-bis(prop-2-yn-1-yloxy)benzoic acid13 (C) 
Methyl 3,5-bis(prop-2-yn-1-yloxy)benzoate was taken up in dioxane/methanol (327.48 
mL/128.52 mL, 14:5 v) and 4 N NaOH (64.29 mL) was added. Reaction was stirred at room 
temperature for 5 hours and then neutralized with 1 M HCl and concentrated. The mixture was 
dissolved in EtOAc and washed with NaHCO3 (3x50 mL) and brine (3x70mL). The organic 
layers were combined, dried over Na2SO4, filtered, and concentrated under reduced pressure to 
give C as a yellow powder (0.247 g, 18%). Rf= 0.29 (30% EtOAc/DCM).  1H NMR 13C NMR 
HRMS (ESI+) = calculated C13H10O4 (M+H+) = 231.0655, found = 231.0652. 
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Preparation of  
methyl 3,5-bis(2-{[3,5-bis(prop-2-yn-1-yloxy)benzoyl]amino}ethoxy)benzoate (A)   
To a solution of 3,5-bis(prop-2-yn-1-yloxy)benzoic acid (0.1 g, 0.434 mmol), HATU (0.165g, 
0.434 mmol), HoBt (0.059g, 0.434 mmol), and DIEA (0.172 mL) in THF (0.2M) was added 
compound 3 (0.05g, 0.197 mmol). Mixture was stirred at room temperature overnight and the 
solvent evaporated. The resulting oil was purified via flash SiO2 column chromatography (5 x 15 
cm, 10% MeOH/DCM) to yield A as yellow oil (59 mg, 44%). Rf= 0.46 (10% MeOH/DCM). 1H 
NMR (300 MHz, CDCl3) δ 7.09 (d, J = 2.32 Hz, 2H), 7.03 (d, J = 2.29 Hz, 4H), 6.70 (t, J = 2.29 
Hz, 2H), 6.56 (t, J = 2.34 Hz, 1H), 4.65 (d, J = 2.40 Hz, 8H), 4.07 (t, J = 5.08 Hz, 4H), 3.85 (d, J 
= 2.43 Hz, 3H), 3.79 (dd, J = 5.29, 10.52 Hz, 4H), 2.52 (t, J = 2.39 Hz, 4H). δ C (75 MHz, 
CDCl3) 39.62 (CH2), 40.97, 52.40 (CH3), 56.18 (CH2), 66.99 (CH2), 76.19 (CH), 77.36 (C), 
78.07 (C), 105.52, 106.87, 108.24, 132.16 (C), 136.62 (C), 158.75 (C), 159.51 (C), 166.55, 
167.27 (C).  HRMS (ESI+) = calculated C38H34N2O10 (M+H+) = 679.2292, found = 679.2287. 
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Preparation of Bradykinin Analog 
The bradykinin analog Fmoc-NH-KGRPPGFSPFR-CONH2 (0.09 mmol) was synthesized using 
microwave assisted solid phase peptide synthesis on rink amide resin. The lysine residue was Mtt 
protected. Following synthesis, functionalization was carried out. 
Mtt Deprotection17 
The lysine was first Mtt deprotected. The resin was washed with a cycle of MeOH and DCM (3x 
5 mL, 3 minutes) and then DCM (2x5 mL, 3 minutes) while stirring, draining between washes. 
DCM (5 mL) was added and the resin was allowed to swell for 5 minutes. A mixture of 94:1:5 
DCM/TFA/TIS (10 mL) was added to the resin and stirred for 3 minutes. After draining, the 
resin was washed with MeOH and then DCM (3x 5ml). The mixture of DCM/TFA/TIS was 
added, the resin was stirred, and washed until the resin no longer displayed a yellow color when 
in solution (10x). Following the last cycle of the DCM/TFA/TIS mixture, the resin was washed 
with MeOH and DCM (3x 5 mL), MeOH (5 mL), and lyophilized. The deprotection was 
confirmed using the Kaiser test. 
 Amine to Azide12 
The free amine of the lysine was then converted to an azide. The resin was swelled in a mixture 
of DCM (560 µL), MeOH (520 µL), diH2O (490 µL), and Et3N (2 µL) for two hours, and then 
drained. While the resin was swelling, NaN3 (1.17 g, 18 mmol) was dissolved in diH2O (2.7 mL) 
and DCM was added (5.4 mL) and cooled to 0°C. Tf2O (605.3 µL, 3.6 mmol) was added 
dropwise to a vigorously stirred solution then allowed to heat to room temperature. The reaction 
was left to proceed for two hours. The DCM layer was then drained, and the aqueous layer was 
washed with DCM (2x2 mL), and the combined DCM layers were washed with saturated 
Na2CO3 (1x2mL). To the swelling resin was added all of the Tf2N in the DCM layers and 
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allowed to stir for 5 minutes. Cu2SO4 (2.7 mg, 0.018 mmol) was taken up in diH2O (30 µL) and 
then added to the resin mixture. The reaction proceeded for 24 hours at room temperature, after 
which the resin was drained and washed with 5 mL each of AcCN, DMF, H2O, 0.1 M EDTA in 
H2O (2x), H2O (2x), MeOH, DCM, and MeOH. The peptide was lyophilized and the Kaiser test 
proved the success of the reaction. 
 Fmoc Deprotection18 
10 mL of a 1:4 v:v piperidine/NMP solution was made and 5 mL was added to the resin. The 
reaction was stirred at room temperature for 30 minutes, after which the resin was drained and 
washed with 5 mL of DMF, MeOH, DMF x2. 5 mL of the remaining piperidine/NMP solution 
was added to the resin and stirred for 30 minutes at room temperature. The resin was washed 
with DMF, (DCM, MeOH) x3 and lyophilized overnight. The Kaiser test confirmed successful 
deprotection.  
 NBD-Ahx Labeling 
NBD-Ahx (44.25mg, 0.15mmol) and HATU (57mg, 0.15mmol) was added to the resin. NMP (2 
mL) and DIPEA (.35 mL, 0.15mmol) were added and the mixture was stirred for two hours at 
room temperature. The resin was drained and washed with (DMF, DCM, MeOH) x3 and 
lyophilized overnight. Kaiser test confirmed labeling. The peptide was cleaved using 85/5/5/5 
TFA/H2O/Phenol/TIPS solution (7.5 mL) and stirring for one hour at room temperature. 
Following cleavage, the peptide was drained into a falcon tube and the frit tube was rinsed with 1 
mL TFA and drained to the falcon tube. Cold Et2O (45mL) was added to the falcon tube and kept 
at -20°C for 15 minutes, then vortexed and centrifuged for 10 minutes at 4500 rpm. The solution 
was decanted and cold Et2O (20 mL) was added, vortex mixed, centrifuged for 10 minutes at 
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4500 rpm, and decanted. The resulting peptide was vacuum dried overnight and then purified by 
gradient reverse-phase HPLC. 
Preparation of Peptide 4 
MeOH and AcCN were purged with N2 for at least 30 minutes prior to start of procedure. The 
TFA-salt of the peptide (15 mg, 0.0079 mmol) was taken up in MeOH (300 µL) and A (1.12 mg, 
0.0017 mmol) was added in MeOH (70 µL). TBTA (7.02 mg, 0.013mmol) and 
tetrakis(acetonitrile)copper(I) hexafluorophosphate (24.68 mg, 0.066 mmol) were added directly. 
A few drops of MeCN were added to bring everything into solution, and then the reaction was 
stirred at room temperature for 20 hours. Then, the sample was quenched with water (1 mL) and 
lyophilized to dryness before purification by reverse-phase HPLC.  
Preparation of Peptide 2 
MeOH and MeCN were purged with N2 for at least 30 minutes prior to start of procedure. The 
TFA-salt of the peptide (7 mg, 0.0037 mmol) was taken up in MeOH (225 µL) and D (0.368 mg, 
0.0015 mmol) was added in MeOH (100 µL). TBTA (6.367 mg, 0.012mmol) and 
tetrakis(acetonitrile)copper(I) hexafluorophosphate (5.59 mg, 0.015 mmol) were added directly. 
A few drops of MeCN were added to bring everything into solution, and then the reaction was 
stirred at room temperature for 20 hours. Then, the sample was quenched with water (1 mL) and 
lyophilized to dryness before purification by reverse-phase HPLC.  
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